Profil bibliographique

Maarten Leyssen

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

47Publications signalées

2259Citations signalées

5Affiliations récentes

Institutions déclarées

Institut national de recherche en sciences et technologies du numérique Université de Bordeaux Inserm Bordeaux Population Health Janssen (Netherlands)

Domaines associés

Viral Infections and Outbreaks ResearchHepatitis B Virus StudiesVaccine Coverage and HesitancyHepatitis Viruses Studies and EpidemiologyHepatitis C virus research

Publications récentes

Accès ouvert 2024 article

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

Simon Valayer, Marie Alexandre, Mélanie Prague, Abdoul Habib Béavogui et autres

4 citationsEmerging Microbes & Infections

Accès ouvert 2024 article

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases

Aurélie Wiedemann, Édouard Lhomme, Mélanie Huchon, Emile Foucat et autres

21 citationsNature Communications

Accès ouvert 2023 article

Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

Andrew W. Lee, Ken Liu, Édouard Lhomme, Julie Blie et autres

18 citationsClinical Infectious Diseases

Accès ouvert 2023 article

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

E Choi, Boris Lacarra, Muhammed O. Afolabi, Boni Maxime Ale et autres

18 citationsThe Lancet Global Health

Accès ouvert 2022 article

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens et autres

21 citationsnpj Vaccines

Accès ouvert 2022 article

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial

Etienne Karita, Julien Nyombayire, Rosine Ingabire, Amelia Mazzei et autres

18 citationsTrials

Accès ouvert 2022 article

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo

Deborah Watson‐Jones, Hugo Kavunga‐Membo, Rebecca F. Grais, Steve Ahuka et autres

31 citationsBMJ Open

Accès ouvert 2022 article

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

Zacchaeus Anywaine, Houreratou Barry, Omu Anzala, Gaudensia Mutua et autres

65 citationsPLoS Medicine

Accès ouvert 2021 article

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

Viki Bockstal, Auguste Gaddah, Neil Goldstein, Georgi Shukarev et autres

10 citationsnpj Vaccines

Accès ouvert 2021 article

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

Houreratou Barry, Gaudensia Mutua, Hannah Kibuuka, Zacchaeus Anywaine et autres

71 citationsPLoS Medicine

Accès ouvert 2021 article

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

Muhammed O. Afolabi, David Ishola, Daniela Manno, Babajide Keshinro et autres

98 citationsThe Lancet Infectious Diseases

Accès ouvert 2021 article

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

David Ishola, Daniela Manno, Muhammed O. Afolabi, Babajide Keshinro et autres

96 citationsThe Lancet Infectious Diseases

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.